Investigational drug · Phase 2
SRD-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Congestive Heart Failure, Heart Failure, Systolic, Heart Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SRD-001"
First trial start
2021
Sep 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SRD-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Congestive Heart Failure
- Heart Failure, Systolic
- Heart Failure
- HFrEF - Heart Failure With Reduced Ejection Fraction
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SRD-001" as an intervention, largest first.
Sardocor Corp.Industry
NCT04703842 · 57 participants (planned) · Start Sep 23, 2021 · Primary completion Dec 31, 2025
Drug: SRD-001; Placebo · For: Congestive Heart Failure; Heart Failure, Systolic; Heart Failure and 1 more
Sites: San Diego, California; San Francisco, California; St Louis, Missouri · 5 sites in all
Sardocor Corp.Industry
NCT06061549 · 10 participants (planned) · Start Aug 24, 2023 · Primary completion Aug 2025
Drug: AAV1/SERCA2a · For: Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction
Sites: Durham, North Carolina; Dallas, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.